Clinical trial NCT04336982: A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
Official title: An Exploratory Phase 1b Open-label Multi-arm Trial to Evaluate the Safety and Efficacy of CC-90009 in Combination With Anti-Leukemia Agents in Subjects With Acute Myeloid Leukemia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Leukemia, Myeloid, Acute
Keywords: CC-90009
Venetoclax
Azacitidine
Gilteritinib
Hematologic cancers
Leukemia
Acute myeloid leukemia
AML
Lead sponsor: Celgene
Sponsor class: INDUSTRY
Collaborators: name: AbbVie
First posted: 2020-04-07
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: CC-90009-AML-002 is an exploratory Phase 1b, open-label, multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute myeloid leukemia (AML).

Detailed description: Study CC-90009-AML-002 is an open-label, multi-arm, parallel multi-cohort, multicenter, Phase 1b study to determine the safety, tolerability, PK, and efficacy of CC 90009 in combination with anti-leukemia agents used for the treatment of AML. CC 90009 will be given as a combination therapy to subjects with newly diagnosed (ND) or relapsed or refractory (R/R) AML.

The dose and schedule finding part (Part A) of the study will evaluate the safety, PK and PD data, and preliminary efficacy information and determine the Part B dose and schedule for each arm.

The expansion part (Part B) of the study will further evaluate the safety and efficacy of the CC-90009 containing combination at or below the maximum tolerated dose (MTD) in the selected cohorts in order to determine the recommended Phase 2 dose (RP2D) for subjects with AML.

Eligibility criteria: Inclusion Criteria:

1. Adult subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
2. Arm A (CC-90009 + venetoclax/azacitidine):

   1. Part A: Newly diagnosed AML with poor/adverse risk genetic abnormalities and is either ≥ 75 years of age or is ineligible for intensive chemotherapy OR
   2. Part A: Primary Refractory AML, or AML in first relapse, and is ≥ 18 years of age
   3. Part B: Newly diagnosed AML and is ≥ 75 years of age or intensive chemotherapy ineligible
3. Arm B (CC-90009 + gilteritinib):

   1. Subject is ≥ 18 years of age.
   2. Fms-like tyrosine kinase 3 (FLT3) mutation positive.
   3. Gilteritinib treatment naïve
4. Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
5. Subject must have the following screening laboratory values:

   * Total White Blood Cell count (WBC) \< 25 x 10\^9/L prior to study treatments. Treatment with hydroxyurea to achieve this level is allowed.
   * Selected electrolytes within normal limits or correctable with supplements.

     * Participant must have adequate liver function as demonstrated by: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) and bilirubin ≤ 1.5 x ULN
     * Participant has adequate renal function as demonstrated by an estimated serum creatinine clearance of ≥ 30 mL/min.
6. Agree to follow the CC-90009 Pregnancy Prevention Plan (PPP) and combination agents' requirements.

Exclusion Criteria:

1. Subject with acute promyelocytic leukemia (APL)
2. Subject has received systemic anticancer therapy (including investigational therapy) or radiotherapy \< 28 days or 5 half-lives, whichever is shorter, prior to the start of study treatment
3. Patients with prior autologous hematopoietic stem cell transplant (HSCT) who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (eg, transplant related side effects)
4. Prior allogeneic HSCT with either standard or reduced intensity conditioning ≤ 6 months prior to dosing
5. Subject on systemic immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). The use of topical steroids for ongoing skin or ocular GVHD is permitted
6. Subject has persistent, clinically significant non-hematologic toxicities from prior therapies which have not recovered to \< Grade 2
7. Subject has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening.
8. Disorders or conditions disrupting normal calcium homeostasis or preventing calcium supplementation.
9. Impaired cardiac function or clinically significant cardiac diseases, including any of the following:

   1. Left ventricular ejection fraction (LVEF) \< 45% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO).
   2. Complete left bundle branch or bifascicular block.
   3. Congenital long QT syndrome.
   4. Persistent or clinically meaningful ventricular arrhythmias.
   5. QTcF ≥ 470 ms (Arm A) or \> 450 ms (Arm B) on Screening electrocardiogram (ECG)
   6. Unstable angina pectoris or myocardial infarction ≤ 6 months prior to starting study treatments or unstable arrhythmia.
   7. Cardiovascular disability status of New York Heart Association Class ≥2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.
10. Subject is a pregnant or lactating female
11. Additional exclusion criteria based on combination agent:

    a. For Combination Arm A (venetoclax/azacitidine):
    * Received strong or moderate CYP3A inhibitors or inducers or P-gp inhibitors within 7 days prior to initiation of first venetoclax dose.
    * Subject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or Star fruit within 3 days prior to first venetoclax dose through last dose of venetoclax.
12. Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D1.

    a. Acute symptoms must have resolved and based on investigator assessment in consultation with the medical monitor, there are no sequelae that would place the participant at a higher risk of receiving study treatment.
13. Previous SARS-CoV-2 vaccine within 14 days of C1D1.

Primary outcomes:
measure: Dose Limiting Toxicity (DLT)
timeFrame: Up to 28 days
measure: Adverse Events (AEs)
timeFrame: Up to 28 days after last dose of study drug.
Secondary outcomes:
measure: Complete Remission Rate (CRR),
timeFrame: Up to 3 years
measure: Objective Response Rate (ORR)
timeFrame: Up to 3 years
measure: Progression Free Survival (PFS)
timeFrame: Up to 3 years
measure: Overall Survival (OS)
timeFrame: Up to 3 years
measure: Duration of Remission
timeFrame: Up to 3 years
measure: Time to Remission
timeFrame: Up to 3 years
measure: Pharmacokinetics - Cmax
timeFrame: Until last CC-90009 dose in Cycle 3 (each cycle is 28 days. CC-90009 dosing days are Days 1-5 in Cycle 3)
measure: Pharmacokinetics - AUC24
timeFrame: Until last CC-90009 dose in Cycle 3 (each cycle is 28 days. CC-90009 dosing days are Days 1-5 in Cycle 3)
measure: Pharmacokinetics - t1/2
timeFrame: Until last CC-90009 dose in Cycle 3 (each cycle is 28 days. CC-90009 dosing days are Days 1-5 in Cycle 3)
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Local Institution - 104
state: California
city: New Haven
country: United States
facility: Local Institution - 107
state: Connecticut
city: Boston
country: United States
facility: Local Institution - 103
state: Massachusetts
city: Saint Louis
country: United States
facility: Local Institution - 101
state: Missouri
city: Hackensack
country: United States
facility: Local Institution - 108
state: New Jersey
city: Houston
country: United States
facility: Local Institution - 105
state: Texas
city: Seattle
country: United States
facility: Local Institution - 102
state: Washington
city: Yvoir
country: Belgium
facility: Local Institution - UNK3
city: Edmonton
country: Canada
facility: Local Institution - 202
state: Alberta
city: Toronto
country: Canada
facility: Local Institution - 201
state: Ontario
city: Marseille
country: France
facility: Local Institution - 402
city: Pessac Cedex
country: France
facility: Local Institution - 401
city: Toulouse Cedex 9
country: France
facility: Local Institution - 404
city: Oxford
country: United Kingdom
facility: Local Institution - 301
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
citation: Surka C, Jin L, Mbong N, Lu CC, Jang IS, Rychak E, Mendy D, Clayton T, Tindall E, Hsu C, Fontanillo C, Tran E, Contreras A, Ng SWK, Matyskiela M, Wang K, Chamberlain P, Cathers B, Carmichael J, Hansen J, Wang JCY, Minden MD, Fan J, Pierce DW, Pourdehnad M, Rolfe M, Lopez-Girona A, Dick JE, Lu G. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood. 2021 Feb 4;137(5):661-677. doi: 10.1182/blood.2020008676.